kl-a167
mAbexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Jul 30, 2018 (NCT03580564)
Timeline
Indications
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05445908 | Phase 2 | Jul 31, 2022 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. |
| NCT05294172 | Phase 3 | Jun 1, 2022 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. |
| NCT05351788 | Phase 2 | Apr 30, 2022 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. |
| NCT03848286 | Phase 2 | Feb 28, 2019 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. |
| NCT03580564 | Phase 2 | Jul 30, 2018 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | For profit | 5 | 5 | 2 | 2018 |
1 organizations
Page 1 / 1